Q-omics provides the consensus-scored LIG4 profile across patient tissues and cancer cell-line models. LIG4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, LIG4 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, LIG4 RNA expression shows 20,129 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, HNSC, and UVM as cancer lineages where LIG4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LIG4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LIG4 survival associations across molecular data types. LIG4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LIG4 RNA expression–survival associations across cancer types. High LIG4 expression shows unfavorable associations in UVM, MESO, ACC and HNSC, but favorable associations in UCEC and KIRC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .009). Together, the overview and detailed table identify UCEC as the clearest survival context for LIG4 RNA expression.
This table summarizes LIG4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LIG4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LIG4 shows lower tumor expression in KIRC, KICH, LUSC, THCA and COAD and higher tumor expression in HNSC. The HNSC box plot shows higher LIG4 RNA expression in tumor versus normal tissue (log2 FC = +0.771, t-test p < 0.001).
This table shows molecular features associated with LIG4 in patient tissues and cancer cell lines. In patient samples, LIG4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LIG4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
